PortalPublikationenBendamustine and rituximab in combination with lenalidomide ...

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

Standard

Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. / Maurer, Christian; Pflug, Natali; Bahlo, Jasmin; Kluth, Sandra; Rhein, Christina; Cramer, Paula; Gross-Ophoff, Carolin; Langerbeins, Petra; Fink, Anna-Maria; Eichhorst, Barbara; Kreuzer, Karl-Anton; Fischer, Norbert; Tausch, Eugen; Stilgenbauer, Stephan; Böttcher, Sebastian; Döhner, Hartmut; Kneba, Michael; Dreyling, Martin; Binder, Mascha; Hallek, Michael; Wendtner, Clemens-Martin; Bergmann, Manuela; Fischer, Kirsten; German CLL Study Group (GCLLSG).

in: EUR J HAEMATOL, 08.12.2015.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Maurer, C, Pflug, N, Bahlo, J, Kluth, S, Rhein, C, Cramer, P, Gross-Ophoff, C, Langerbeins, P, Fink, A-M, Eichhorst, B, Kreuzer, K-A, Fischer, N, Tausch, E, Stilgenbauer, S, Böttcher, S, Döhner, H, Kneba, M, Dreyling, M, Binder, M, Hallek, M, Wendtner, C-M, Bergmann, M, Fischer, K & German CLL Study Group (GCLLSG) 2015, 'Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia', EUR J HAEMATOL. https://doi.org/10.1111/ejh.12714

APA

Maurer, C., Pflug, N., Bahlo, J., Kluth, S., Rhein, C., Cramer, P., Gross-Ophoff, C., Langerbeins, P., Fink, A-M., Eichhorst, B., Kreuzer, K-A., Fischer, N., Tausch, E., Stilgenbauer, S., Böttcher, S., Döhner, H., Kneba, M., Dreyling, M., Binder, M., ... German CLL Study Group (GCLLSG) (2015). Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. EUR J HAEMATOL. https://doi.org/10.1111/ejh.12714

Vancouver

Maurer C, Pflug N, Bahlo J, Kluth S, Rhein C, Cramer P et al. Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia. EUR J HAEMATOL. 2015 Dez 8. https://doi.org/10.1111/ejh.12714

Bibtex

@article{025fa9b2fc354408b3a233145620bfc4,
title = "Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia",
abstract = "PURPOSE: A phase I/II trial to assess safety and efficacy of the combination bendamustine, rituximab, and lenalidomide (BRL) in patients with chronic lymphocytic leukemia (CLL).PATIENTS AND METHODS: Seventeen relapsed or refractory (R/R) and five previously untreated (FL) CLL patients were enrolled in the trial. In the R/R cohort, four different dose levels of lenalidomide (maximum 15 mg/d) were used. In the FL cohort, lenalidomide was dose escalated from 5 mg/d to 15 mg/d. Bendamustine was used at doses of 50 or 90 mg/m(2) for R/R or FL treatment, respectively. 375 mg/m(2) Rituximab were used for the first and 500 mg/m(2) for subsequent treatment courses. Treatment consisted of up to six courses of 28 d.RESULTS: The maximal tolerable dose of lenalidomide was 5 mg/d. The response rate was 47.1% in R/R and 60% in FL patients. Median progression-free survival was 8.0 months. Median overall survival was 22.9 and 12.3 months, respectively, in R/R and FL patients. Grade 3/4 hematological toxicity was observed in 71.4%, and severe infections in 47.6% of patients. Due to high toxicity and low response rate of BRL, the trial was closed prematurely.CONCLUSION: BRL was associated with a high toxicity rate, a high number of treatment interruptions, and a low remission rate. Therefore, BRL cannot be considered an appropriate treatment option for patients with CLL.",
author = "Christian Maurer and Natali Pflug and Jasmin Bahlo and Sandra Kluth and Christina Rhein and Paula Cramer and Carolin Gross-Ophoff and Petra Langerbeins and Anna-Maria Fink and Barbara Eichhorst and Karl-Anton Kreuzer and Norbert Fischer and Eugen Tausch and Stephan Stilgenbauer and Sebastian B{\"o}ttcher and Hartmut D{\"o}hner and Michael Kneba and Martin Dreyling and Mascha Binder and Michael Hallek and Clemens-Martin Wendtner and Manuela Bergmann and Kirsten Fischer and {German CLL Study Group (GCLLSG)}",
note = "{\textcopyright} 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.",
year = "2015",
month = dec,
day = "8",
doi = "10.1111/ejh.12714",
language = "English",
journal = "EUR J HAEMATOL",
issn = "0902-4441",
publisher = "Wiley-Blackwell",

}

RIS

TY - JOUR

T1 - Bendamustine and rituximab in combination with lenalidomide in patients with chronic lymphocytic leukemia

AU - Maurer, Christian

AU - Pflug, Natali

AU - Bahlo, Jasmin

AU - Kluth, Sandra

AU - Rhein, Christina

AU - Cramer, Paula

AU - Gross-Ophoff, Carolin

AU - Langerbeins, Petra

AU - Fink, Anna-Maria

AU - Eichhorst, Barbara

AU - Kreuzer, Karl-Anton

AU - Fischer, Norbert

AU - Tausch, Eugen

AU - Stilgenbauer, Stephan

AU - Böttcher, Sebastian

AU - Döhner, Hartmut

AU - Kneba, Michael

AU - Dreyling, Martin

AU - Binder, Mascha

AU - Hallek, Michael

AU - Wendtner, Clemens-Martin

AU - Bergmann, Manuela

AU - Fischer, Kirsten

AU - German CLL Study Group (GCLLSG)

N1 - © 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

PY - 2015/12/8

Y1 - 2015/12/8

N2 - PURPOSE: A phase I/II trial to assess safety and efficacy of the combination bendamustine, rituximab, and lenalidomide (BRL) in patients with chronic lymphocytic leukemia (CLL).PATIENTS AND METHODS: Seventeen relapsed or refractory (R/R) and five previously untreated (FL) CLL patients were enrolled in the trial. In the R/R cohort, four different dose levels of lenalidomide (maximum 15 mg/d) were used. In the FL cohort, lenalidomide was dose escalated from 5 mg/d to 15 mg/d. Bendamustine was used at doses of 50 or 90 mg/m(2) for R/R or FL treatment, respectively. 375 mg/m(2) Rituximab were used for the first and 500 mg/m(2) for subsequent treatment courses. Treatment consisted of up to six courses of 28 d.RESULTS: The maximal tolerable dose of lenalidomide was 5 mg/d. The response rate was 47.1% in R/R and 60% in FL patients. Median progression-free survival was 8.0 months. Median overall survival was 22.9 and 12.3 months, respectively, in R/R and FL patients. Grade 3/4 hematological toxicity was observed in 71.4%, and severe infections in 47.6% of patients. Due to high toxicity and low response rate of BRL, the trial was closed prematurely.CONCLUSION: BRL was associated with a high toxicity rate, a high number of treatment interruptions, and a low remission rate. Therefore, BRL cannot be considered an appropriate treatment option for patients with CLL.

AB - PURPOSE: A phase I/II trial to assess safety and efficacy of the combination bendamustine, rituximab, and lenalidomide (BRL) in patients with chronic lymphocytic leukemia (CLL).PATIENTS AND METHODS: Seventeen relapsed or refractory (R/R) and five previously untreated (FL) CLL patients were enrolled in the trial. In the R/R cohort, four different dose levels of lenalidomide (maximum 15 mg/d) were used. In the FL cohort, lenalidomide was dose escalated from 5 mg/d to 15 mg/d. Bendamustine was used at doses of 50 or 90 mg/m(2) for R/R or FL treatment, respectively. 375 mg/m(2) Rituximab were used for the first and 500 mg/m(2) for subsequent treatment courses. Treatment consisted of up to six courses of 28 d.RESULTS: The maximal tolerable dose of lenalidomide was 5 mg/d. The response rate was 47.1% in R/R and 60% in FL patients. Median progression-free survival was 8.0 months. Median overall survival was 22.9 and 12.3 months, respectively, in R/R and FL patients. Grade 3/4 hematological toxicity was observed in 71.4%, and severe infections in 47.6% of patients. Due to high toxicity and low response rate of BRL, the trial was closed prematurely.CONCLUSION: BRL was associated with a high toxicity rate, a high number of treatment interruptions, and a low remission rate. Therefore, BRL cannot be considered an appropriate treatment option for patients with CLL.

U2 - 10.1111/ejh.12714

DO - 10.1111/ejh.12714

M3 - SCORING: Journal article

C2 - 26643449

JO - EUR J HAEMATOL

JF - EUR J HAEMATOL

SN - 0902-4441

ER -